Welcome to our dedicated page for CNS Pharmaceuticals news (Ticker: CNSP), a resource for investors and traders seeking the latest updates and insights on CNS Pharmaceuticals stock.
CNS Pharmaceuticals, Inc. (NASDAQ: CNSP) is a Houston-based clinical-stage biopharmaceutical company established in 2017. The company is dedicated to developing novel anticancer drug candidates aimed at treating primary and metastatic cancers of the brain and central nervous system (CNS). Their lead drug candidate, Berubicin, is a pioneering anthracycline that distinguishes itself by its ability to cross the blood-brain barrier, offering new hope for patients suffering from glioblastoma multiforme (GBM), an aggressive and currently incurable form of brain cancer.
Berubicin has shown promise in initial trials, with the Phase I clinical trial completing successfully. As of now, Berubicin is being evaluated in a potentially pivotal study. The preliminary safety data was presented at the Society of NeuroOncology (SNO) 28th Annual Meeting, highlighting its comparability in patient demographics and safety with the control arm of the study. Encouragingly, the independent Data Safety Monitoring Board (DSMB) recommended the continuation of the trial without modification after a pre-planned interim futility analysis, signifying Berubicin’s acceptable efficacy and safety profile.
The company has also secured several important collaborations and licensing agreements, including partnerships with Houston Pharmaceuticals, Inc., the University of Texas M.D. Anderson Cancer Center, and WPD Pharmaceuticals Inc. These agreements bolster the development pipeline and provide access to cutting-edge research and development facilities.
Financially, CNS Pharmaceuticals is proactive in securing necessary funding for their research endeavors. Recent public offerings and strategic financial management have ensured operational continuity and support for their ongoing clinical trials. Despite the inherent risks and uncertainties of drug development, CNS Pharmaceuticals remains steadfast in their mission to develop effective cancer therapies.
Beyond Berubicin, CNS Pharmaceuticals continues to explore additional drug candidates and therapies to address various CNS oncology indications. The company's commitment to innovation and patient care positions it as a potential leader in the fight against some of the most challenging cancer types.
For more information, please visit www.CNSPharma.com and connect with the company on Twitter, Facebook, and LinkedIn.
CNS Pharmaceuticals (NASDAQ:CNSP) announced that its abstract has been accepted for poster presentation at the 29th Annual Meeting of the Society for Neuro-Oncology (SNO 2024), taking place November 21-24, 2024 in Houston, TX. The presentation, titled 'Update on a Potentially Pivotal Trial CNS-201: A Randomized, Controlled Trial of Berubicin Vs. Lomustine After First-Line Therapy for Glioblastoma Multiforme (GBM)', will be presented by Chief Medical Officer Sandra Silberman, MD, PhD, on November 22, 2024.
CNS Pharmaceuticals (NASDAQ:CNSP) reported Q3 2024 financial results, highlighting progress in its clinical development programs. The company completed enrollment of 252 patients in its pivotal Berubicin GBM study, with primary analysis data expected in H1 2025. Net loss increased to $5.6 million from $4.5 million year-over-year. R&D expenses rose to $4.2 million from $3.4 million. The company strengthened its cash position to $7.0 million, supplemented by post-quarter fundraising of $4.6 million, extending operations through Q2 2025. Additionally, CNS expanded its pipeline by in-licensing TPI 287, a late-stage brain malignancy treatment.
CNS Pharmaceuticals (NASDAQ:CNSP) announced its participation in a Virtual Investor KOL Connect segment featuring Professor Michael Weller, Chairman of the Department of Neurology at the University Hospital in Zurich and National Coordinating Investigator for CNS's Berubicin study. The segment focused on glioblastoma multiforme (GBM), discussing unmet medical needs, current treatments, and Berubicin's potential as a solution for this condition.
CNS Pharmaceuticals (NASDAQ:CNSP) has received an extension from the Nasdaq Hearings Panel until March 11, 2025, to meet the minimum bid price requirement under Listing Rule 5550(a)(2). The company, which develops treatments for primary and metastatic brain and central nervous system cancers, now has additional time to regain compliance with Nasdaq's listing requirements.
CNS Pharmaceuticals (NASDAQ:CNSP) has announced a registered direct offering of 17,647,060 shares of common stock priced at-the-market at $0.17 per share. The offering, expected to close around October 24, 2024, aims to raise approximately $3 million in gross proceeds. The company plans to use the net proceeds for working capital and general corporate purposes. A.G.P./Alliance Global Partners is serving as the sole placement agent for this offering, which is being conducted under an effective shelf registration statement.
CNS Pharmaceuticals, Inc. (NASDAQ:CNSP), a biopharmaceutical company focused on developing novel treatments for brain and central nervous system cancers, announced its participation in a Virtual Investor KOL Connect segment. The event featured key members of the CNS management team, including:
- John Climaco, Chief Executive Officer
- Dr. Sandra Silberman, Chief Medical Officer
- Dr. Don Picker, Chief Scientific Officer
Additionally, Dr. Samuel Goldlust, a leading Neuro-Oncologist and Key Opinion Leader, joined the segment. Dr. Goldlust currently serves as the Medical Director of Neuro-Oncology at Saint Luke's Health System and was previously an investigator in CNS's global potentially pivotal study of Berubicin.
The segment covered a corporate overview, discussed the unmet need in glioblastoma multiforme (GBM), and explored the opportunities for CNS Pharmaceuticals in this field.
CNS Pharmaceuticals, Inc. (NASDAQ:CNSP), a biopharmaceutical company focused on developing novel treatments for brain and central nervous system cancers, has announced its participation in the 2024 Healthcare Virtual Summit presented by Maxim Group John Climaco, CEO of CNS Pharmaceuticals, will engage in a fireside chat on Wednesday, October 16th at 4:00 PM ET.
The summit will feature a series of presentations and interactive discussions with CEOs and key management from various healthcare sectors, including biotechnology, diagnostics, medical devices, and healthcare information technology. Maxim Senior Analysts will host these sessions and conduct several topical industry panels.
Interested participants can attend the virtual event by signing up for an M-Vest membership. Further updates about the summit will be provided to registered attendees.
CNS Pharmaceuticals (NASDAQ:CNSP), a biopharmaceutical company focused on developing novel treatments for brain and central nervous system cancers, has announced its participation in the 24th Annual Biotech in Europe Forum. John Climaco, the company's CEO, is scheduled to present on Wednesday, September 25, 2024, at 1:55 PM CEST in Basel, Switzerland.
The presentation will be available as a video webcast on demand for registered attendees through the conference presenters portal. Additionally, the company's management team will be available for in-person one-on-one meetings with qualified investors attending the conference.
This event provides CNS Pharmaceuticals with an opportunity to showcase its developments in primary and metastatic cancer treatments, potentially attracting investor interest and fostering industry connections.
CNS Pharmaceuticals (NASDAQ:CNSP), a biopharmaceutical company focused on developing novel treatments for brain and central nervous system cancers, has regained compliance with Nasdaq's equity requirement. The company received notice from Nasdaq on September 10, 2024, confirming its compliance with Listing Rule 5550(b)(1). This development is subject to a one-year Nasdaq Mandatory Panel Monitor related to the equity requirement. With this compliance issue resolved, Nasdaq has informed CNS Pharmaceuticals that the matter is now closed.
CNS Pharmaceuticals (NASDAQ:CNSP), a biopharmaceutical company focused on developing novel treatments for brain and central nervous system cancers, has announced its participation in the H.C. Wainwright 26th Annual Global Investment Conference. The event is scheduled for September 9-11, 2024, in New York, NY.
Key points:
- CEO John Climaco will present at the conference
- Management will be available for one-on-one meetings with qualified investors
- A video webcast of the presentation will be available on-demand from September 9, 2024, at 7:00 AM ET
- The webcast will be accessible on the Company's website and archived for 90 days
This presentation offers an opportunity for CNS Pharmaceuticals to showcase its developments and engage with the investment community.
FAQ
What is the current stock price of CNS Pharmaceuticals (CNSP)?
What is the market cap of CNS Pharmaceuticals (CNSP)?
What is CNS Pharmaceuticals' primary focus?
What is Berubicin?
What makes Berubicin different from other cancer treatments?
What stage is Berubicin currently in?
What recent achievements has CNS Pharmaceuticals reported?
Who are CNS Pharmaceuticals' key partners?
What financial steps has CNS Pharmaceuticals taken recently?
What designations has the FDA granted to Berubicin?
What is the primary endpoint of the Berubicin study?
How does CNS Pharmaceuticals ensure the accuracy and safety of its trials?
